A Moderna or BioNTech in its early days, but focused on novel treatments for rare genetic diseases.

An early-stage Vertex Pharmaceuticals, focused on developing drugs for rare genetic diseases, including cystic fibrosis.

• ELX-02: An investigational drug candidate in Phase 2 clinical trials for the treatment of cystic fibrosis and nephropathic cystinosis patients with nonsense mutations.
• Preclinical Programs: Drug development programs in preclinical stages targeting alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis.
• Discovery Stage Oncology Programs: Earlier research and development programs focused on potential oncology treatments.

Eloxx Pharmaceuticals (NASDAQ: ELOX) is a clinical-stage biopharmaceutical company. As described in the background, its lead investigational drug candidate, ELX-02, is currently in Phase 2 clinical trials. The company's focus is on research, development, and clinical trials for rare and ultra-rare premature stop codon diseases.

Given that Eloxx Pharmaceuticals is a clinical-stage company and its products are still in the development and trial phases, it does not currently have commercialized drug products available for sale. Therefore, Eloxx Pharmaceuticals does not have major customers or categories of customers in the traditional sense, as its investigational drugs are not yet approved for commercial distribution to patients or healthcare providers.

Eloxx Pharmaceuticals' major suppliers include:

• Lonza Ltd. (Symbol: LONN)
• Catalent, Inc. (Symbol: CTLT)

Sumit Aggarwal, President and Chief Executive Officer

Sumit Aggarwal joined Eloxx Pharmaceuticals as President and Chief Executive Officer on April 1, 2021. He previously served as President and CEO and a director of Zikani Therapeutics since 2019. Mr. Aggarwal initially joined Zikani in 2018 as Chief Financial Officer and Chief Business Officer, where he was instrumental in transforming the company into a rare disease and oncology-focused organization. Prior to his time at Zikani, from 2015 to 2018, Mr. Aggarwal was the acting President and Chief Financial Officer of Progenity, Inc., a private genetic services company.

Daniel Geffken, Interim Chief Financial Officer

Daniel Geffken was appointed as Interim Chief Financial Officer on April 1, 2021. He is a founder and managing director of Danforth Advisors, a prominent financial and strategic consulting firm specializing in the life sciences industry. With over 30 years of financial experience, Mr. Geffken has served as CFO and strategic consultant to a wide array of life science and biotechnology companies, from startups to publicly traded entities. He has played a key role in numerous financial transactions, including participating in at least eleven initial public offerings since 2013, and has helped life science companies raise over $2 billion in equity and debt securities throughout his career. Notably, as CFO of Transkaryotic Therapies, he led five equity transactions that raised $600 million, including what was, at the time, the largest private placement in biotechnology history. His extensive experience as a consultant and interim CFO for numerous private and public biopharmaceutical companies, coupled with his significant fundraising activities including private placements, indicates a pattern of engagement with companies that are often backed by private equity firms.

Ali Hariri, Chief Medical Officer

Ali Hariri, M.D., was appointed Chief Medical Officer of Eloxx Pharmaceuticals on September 8, 2021, where he oversees the company's clinical development efforts for its pipeline of rare disease therapies. Before joining Eloxx, Dr. Hariri served as Senior Global Project Head in Rare Disease Clinical Development at Sanofi, specifically within the Sanofi Genzyme specialty care business. In this role, he managed key functions involved in advancing investigational therapies and securing approvals for on-market products. Prior to Sanofi, Dr. Hariri held clinical development and medical affairs positions at Ionis Pharmaceuticals and Takeda. He also practiced as a nephrologist.

The key risks to Eloxx Pharmaceuticals (ELOX) are primarily centered around its status as a clinical-stage biopharmaceutical company with no approved products and a heavy reliance on its drug development pipeline.

1. Clinical Trial Failure and Pipeline Dependency: Eloxx Pharmaceuticals' valuation is almost entirely tied to the success of its lead product candidate, ELX-02, and its other preclinical programs. The company currently has no products approved for sale. ELX-02 is in Phase 2 clinical trials for nephropathic cystinosis and Alport syndrome, having previously failed to achieve statistical significance in a Phase 2 trial for cystic fibrosis, leading to a halt in its development for that indication. Clinical drug development is a lengthy, expensive process with an uncertain outcome and a high probability of failure at various stages. Unfavorable trial results could lead to a catastrophic drop in stock value as the company's entire future rests on these assets.

2. Going Concern and Funding Challenges: As a clinical-stage company, Eloxx Pharmaceuticals incurs significant operating losses and generates no sales revenue. The company reported a net loss of $3.8 million for the quarter ended March 31, 2026, and had only $6.4 million in cash, cash equivalents, and restricted cash. Management and auditors have explicitly stated "substantial doubt about the company's ability to continue as a going concern, absent additional capital." Developing new drugs requires hundreds of millions of dollars over many years, necessitating constant capital raises, often through issuing new shares which dilutes existing shareholders. The company has been noted to have less than a year of cash runway based on free cash flow trends.

3. Regulatory Approval Risk and Development Delays: Even if clinical trials demonstrate efficacy and safety, there is no guarantee that regulatory bodies like the FDA will grant approval for Eloxx's drug candidates. Regulatory agencies can impose clinical holds, demand larger or more expensive additional trials, or outright deny approval, regardless of a drug's therapeutic potential. The regulatory landscape is constantly evolving, with shifting requirements that can impact study design or trial endpoints. Any delays in the regulatory process can significantly drain the company's limited cash reserves and push back potential commercialization.

Eloxx Pharmaceuticals (ELOX) focuses on developing treatments for rare and ultra-rare premature stop codon diseases, with its lead investigational drug product, ELX-02, targeting cystic fibrosis and nephropathic cystinosis.

Addressable Markets:

• Cystic Fibrosis (CF): The global cystic fibrosis market size was valued at USD 5.12 billion in 2019 and is projected to reach USD 62.57 billion by 2032. North America held the largest share of this market, accounting for 75.98% in 2019. More recently, the global cystic fibrosis therapeutics market size was calculated at USD 13.49 billion in 2026 and is projected to reach approximately USD 44.72 billion by 2035. The cystic fibrosis market across the seven major markets (7MM: the U.S., France, Germany, Italy, Spain, the U.K., and Canada) is forecast to grow from USD 11.1 billion in 2024 to USD 16.0 billion in 2034. In 2023, the Cystic Fibrosis Market Size in the 7MM was approximately USD 18,743 million, with the U.S. alone accounting for approximately USD 9,473 million.
• Nephropathic Cystinosis: The global nephropathic cystinosis treatment industry was valued at US$ 332.5 million in 2023 and is projected to reach more than US$ 744.3 million by 2034. The market size for cystinosis in the leading markets (U.S., EU4 countries - Germany, France, Italy, and Spain, the U.K., and Japan) was USD 250 million in 2024. The U.S. accounted for approximately 84% of the total market size in the 7MM in 2024. The global cystinosis treatment market size is estimated to be valued at USD 235 million in 2026 and is expected to reach USD 465 million by 2033. North America dominates this market with more than 40% industry share.

Eloxx Pharmaceuticals (symbol: ELOX) has several anticipated drivers for future revenue growth over the next 2-3 years, stemming primarily from the advancement and potential commercialization of its investigational drug candidates and strategic partnerships:

1. Milestone Payments and Royalties from Partnered Asset ZKN-013: Eloxx Pharmaceuticals entered into an exclusive global license agreement with Almirall, S.A. for ZKN-013, an investigational product for orphan dermatological diseases such as Recessive Dystrophic Epidermolysis Bullosa (RDEB) and Junctional Epidermolysis Bullosa (JEB), and Familial Adenomatous Polyposis (FAP). Under this agreement, Eloxx is eligible to receive significant development, regulatory, and sales milestones of up to $470 million, in addition to tiered royalties on any potential global sales. The company has already received an upfront payment and a $3.0 million milestone in 2024, indicating this as an active revenue stream.
2. Commercialization of ELX-02 for Alport Syndrome with Nonsense Mutations: Eloxx's lead investigational drug candidate, ELX-02, is progressing in clinical development for Alport Syndrome patients with nonsense mutations. The company received positive feedback and guidance from the FDA in July 2024, outlining a pathway for an Investigational New Drug (IND) application to initiate a validating Phase 2 clinical trial in the U.S. Furthermore, ELX-02 was granted Orphan Drug Designation for Alport Syndrome in April 2024. Eloxx initiated Phase 2b planning for exaluren (ELX-02) in nonsense mutation Alport Syndrome in the first half of 2026, with 16-week placebo-controlled data expected by mid-2027 and final results by the end of 2027. Successful clinical development and regulatory approval in this rare disease could lead to significant product revenue.
3. Commercialization of ELX-02 for Cystic Fibrosis and Nephropathic Cystinosis: ELX-02 is also in Phase 2 clinical trials for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. (As per Background) The potential launch of ELX-02 for these indications in major markets, with market forecasts extending to 2030, represents a substantial long-term revenue opportunity.
4. Pipeline Expansion of ELX-02 into New Indications like nmADPKD: Beyond its current lead indications, Eloxx plans to expand the clinical development of ELX-02. This includes initiating a Phase 2 trial of exaluren in nonsense mutation Autosomal Dominant Polycystic Kidney Disease (nmADPKD) in 2027, with anticipated topline data by mid-2028. This expansion into additional rare kidney diseases, if successful, could unlock new patient populations and contribute to future revenue growth.

Share Issuance

• In June 2026, Eloxx Pharmaceuticals priced a public offering to raise approximately $66.0 million in gross proceeds, comprising 2,975,000 common shares at $11.00 each and pre-funded warrants for up to 3,025,000 shares at $10.99 per warrant.
• The company engaged in a follow-on offering in October 2021, raising $119 million.
• Eloxx Pharmaceuticals also conducted follow-on offerings in February 2023 for $125 million and in December 2023 for $150 million.

Inbound Investments

• In August 2025, Coastlands Capital Partners LP invested $15.0 million in the company, and Domicilium invested an additional $2.0 million.

Capital Expenditures

• Eloxx Pharmaceuticals reported $0.00 million in capital expenditures for the trailing twelve months ending December 2025.
• The cash flow for capital expenditures for the six months ended December 2025 was also $0.00 million.